Læknaneminn - 01.04.1996, Qupperneq 37

Æðakölkun - er gátan leyst?
HEIMILDIR
1. Dzau VJ. Pathobiology of atherosclerosis and plaque com-
plications. Am Heart J 1994; 128:6 Pt 2: 1300-1303.
2. Óskar Jónsson. Æðaþel - hvað með það. Læknaneminn
1995 48; 1 tb: 54-63.
3. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in
cardiovascular disease. Review. N Engl J Med 1995; 332:
512-521.
4. Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical
vasoconstriction induced by acetylcholine in atheroscler-
otic coronary arteries. N Engl. J Med 1986; 315:1046-
1051.
5. Golio P, Piscione E Willerson Jt et al. Divergence effect of
serotonin on coronary artery dimension and blood flow in
patients with coronary atherosclerosis and control pati-
ents. N Engl J Med 1991; 324: 641-648.
6. Egashira K, Inou T, Yoshitaka H, Yamada A, Urabe Y,
Takeshita A. Evidence of impaired endothelin-dependent
coronary vasodilation in patients with angina pectoris and
normal coronary angiograms. N Engl J Med 1993; 328:
1659-1664.
7. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Furman
B, Lefer AM. Cardiovascular effects of acute hypercho-
lesteremia in rabits. J Clin Invest 1989; 83: 465-473.
8. Schmieder RE, Schobel HP. Is endothelial dysfunction
reversible? Am J Cardiol 1995; 76: 117A-121A.
9. Furchgott R, Zawadzki JV. The obligatory role of the
endothelium cells in relaxation of arterial smooth muscle
by acetylcholine. Nature 1980; 288: 373-376.
10. Liao JK, Bettmann MA, Sander T, Tucker JI, Coleman
SM, Creager MA. Differential impairment of vasodilator
responsiveness of peripheral resistance and conduit vessels
in human with atherosclerosis. Circ Res 1991; 68: 1027-
1034.
11. Anderson TJ. Gerhard MD, Meredith IT, Charbonneau F,
Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic
nature of endothelial dysfunction in atherosclerosis. Revi-
ew. Am J Cardiol 1995; 75: 71B-74B.
12. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stilla-
bower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedar-
holm JC, Alexander RW. Beneficial eflfects of cholesterol-
lowering therapy on the coronary endothelium in patient
with coronary artery disease. N Engl J Med 1995; 332:
481-487.
13. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP,
Ganz P. The effect of cholesterol-lowering and antioxidant
therapy on endothelium-dependent coronary vasomotion.
N Engl J Med 1995; 332: 488-93.
14. Scandinavian Simvastatin Survival Study Group.
Randomized trial of cholesterol lowering in 4444 patients
with coronary heart disease: The Scandinavina Simavasta-
tin Survival Study (4S). Lancet 1994; 344:1383-1389.
15. Harrison Dg, Ohara Y. Physiologic consequences of incr-
eased vascular oxidant stresses in hypercholesteremia and
atherosclerosis: Implication for impaired vasomotion. Am
J Cardiol 1995; 75: 75B-81B.
16. Alexander RW. Theodore Cooper Memorial Lecture.
Hypertension and the pathogenesis of atherosclerosis. Ox-
idative stress and the mediation of arterial inflammatory
response: A new perspective. Hypertension 1995; 25; 155-
161.
17. Liao F, Audalibi A, DeBeer FC, Fogelman AM, Lusis AJ.
Genetic control of inflammatory gene induction and tran-
scription factor NF-kB activator in response to an ather-
ogenic diet in mice. J Clin Invest 1993; 91: 2572-2579.
18. Liao F, Audalibi A, Lusis AJ, Fogelman AM. Genetic con-
trol of the inflammatory response induced by oxidized
lipids. Review. Am J Cardiol 1995; 75: 65B-66B.
19. Guyton JR. The role of lipoproteins in therogenesis. Nut-
rition and Biotechnology in Heart Disease and Cancer
1995. Plenum Press. NewYork.
20. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of
a mononuclear leukocyte adhesion molecule during ather-
ogenesis. Science 1991; 251: 788-791.
21. JangY, LincoffAM, PlowEF,Topol EJ. Cell adhesion mo-
lecules in coronary artery disease. Review. J Am Coll
Cardiol 1994; 24: 1591-1601.
22. Cushing SD. BerlinerJA, Valeute AJ, Territo MC, Navab
M, Parhani F, Gerrity R, Schwartz Cj, Fogelman AM.
Minnimally modified low density lipoproteins induces
monocyte chemotactic protein (MCP-1) in human endot-
helial and smooth muscle cells. Pro Natl Acad Sci 1990;
87: 5134-5138.
23. Rajavashisth TB, Andolibi A, Territo MC, Berline JA,
Navab, Fogelman AM, Lusis AJ. Modified low density
lipoproteins induce endothelial cell expression of granu-
locyte and macrophage colony stimulating factors. Nature
1990; 344: 254-257.
24. Gimbrone MA Jr. Vascular endothelium: An integrator of
pathophysiologic stimuli in atherosclerosis. Am J Cardiol
1995; 75: 67B-70B.
25. Brown MS, Goldsten JL. Scavenging for receptors. Nature
1990; 343: 508-509.
26. Berliner JA, Naveb M, Fogelman AM, Frank JS, Demer
LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis:
Basic mechanisms. Oxidation, inflammation and genetics.
Review. Circulation 1995; 91: 2488-2496.
27. Libby P. Molecular bases of the acute coronary syndromes.
Review. Circulation 1995; 91: 2844-2850.
28. Falk E, Shah PK, Fuster V. Coronary plaque disruption.
Review. Circulation 1995; 92: 657-671.
29. Jacob HS. Newly recognized causes of atherosclerosis: The
role of microorganisms and of vascular iron overload. J Lac
Clin Med 1994; 123: 808-816.
30. Balla J, Jacob HS, Balla G Nath K Eaton JW, Vercellotti
LÆKNANEMINN
31
1. tbl. 1996, 49. árg.